Deep Dive Into Kymera Therapeutics Stock: Analyst Perspectives (4 Ratings)
Portfolio Pulse from Benzinga Insights
Kymera Therapeutics (NASDAQ:KYMR) has been evaluated by 4 analysts in the past quarter, with 1 bullish, 1 somewhat bullish, and 2 indifferent ratings. The average price target is now $29.5, down from the previous $60.00, indicating a 50.83% decline. Analysts from Wells Fargo, Morgan Stanley, Piper Sandler, and HC Wainwright & Co. have adjusted their price targets and ratings, reflecting changes in market conditions and company performance. Kymera is a biotech company focused on targeted protein degradation to treat diseases. Despite a significant decline in revenue growth and below-average ROA, the company has a strong net margin and ROE, with a low debt-to-equity ratio.
December 19, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Kymera Therapeutics has mixed analyst ratings with a significantly lowered average price target of $29.5, suggesting analysts see limited upside potential in the short term.
The substantial decrease in the average price target for KYMR by analysts reflects a bearish sentiment, which could lead to a negative short-term impact on the stock price. The decline in revenue growth and below-average ROA are concerning, although the strong net margin and ROE, along with a low debt-to-equity ratio, provide some positive aspects. However, the overall negative trend in analyst expectations is likely to weigh more heavily on investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100